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Abstract
Background: Clinical laboratory reference intervals have not been established in many African countries, and non-local
intervals are commonly used in clinical trials to screen and monitor adverse events (AEs) among African participants. Using
laboratory reference intervals derived from other populations excludes potential trial volunteers in Africa and makes AE
assessment challenging. The objective of this study was to establish clinical laboratory reference intervals for 25 hematology,
immunology and biochemistry values among healthy African adults typical of those who might join a clinical trial.
Methods and Findings: Equal proportions of men and women were invited to participate in a cross sectional study at seven
clinical centers (Kigali, Rwanda; Masaka and Entebbe, Uganda; two in Nairobi and one in Kilifi, Kenya; and Lusaka, Zambia).
All laboratories used hematology, immunology and biochemistry analyzers validated by an independent clinical laboratory.
Clinical and Laboratory Standards Institute guidelines were followed to create study consensus intervals. For comparison, AE
grading criteria published by the U.S. National Institute of Allergy and Infectious Diseases Division of AIDS (DAIDS) and other
U.S. reference intervals were used. 2,990 potential volunteers were screened, and 2,105 (1,083 men and 1,022 women) were
included in the analysis. While some significant gender and regional differences were observed, creating consensus African
study intervals from the complete data was possible for 18 of the 25 analytes. Compared to reference intervals from the U.S.,
we found lower hematocrit and hemoglobin levels, particularly among women, lower white blood cell and neutrophil
counts, and lower amylase. Both genders had elevated eosinophil counts, immunoglobulin G, total and direct bilirubin,
lactate dehydrogenase and creatine phosphokinase, the latter being more pronounced among women. When graded
against U.S.-derived DAIDS AE grading criteria, we observed 774 (35.3%) volunteers with grade one or higher results; 314
(14.9%) had elevated total bilirubin, and 201 (9.6%) had low neutrophil counts. These otherwise healthy volunteers would
be excluded or would require special exemption to participate in many clinical trials.
Conclusions: To accelerate clinical trials in Africa, and to improve their scientific validity, locally appropriate reference ranges
should be used. This study provides ranges that will inform inclusion criteria and evaluation of adverse events for studies in
these regions of Africa.
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Introduction
Clinical trials are increasingly being conducted in Africa,
especially trials of preventive interventions for HIV, tuberculosis
and malaria. Great strides have been made towards improving the
research infrastructure worldwide, especially in Africa [1,2].
However, laboratory reference intervals used for trial screening
and evaluating adverse events (AE) have often been derived from
predominantly North American and European (largely Caucasian)
populations [3]; use of these reference intervals may lead to
unnecessary exclusion of potential participants.. Previous studies
from Eastern and Southern African populations indicate differ-
ences in hematology and immunology values, including lower
values for hemoglobin, hematocrit, red blood cell count (RBC),
platelets, mean corpuscular volume (MCV) [4,5,6,7,8,9] and
neutrophils and increased values for monocytes and eosinophils
[5,7,9,10,11]. Lymphocyte and CD4 T cell counts in Africans
have also been reported to be lower than intervals measured in
Europe and North America [9,12,13]. Other studies have noted
hematology and CD4 T cell count variations across different
regions of Africa [5,9,14]. Within the U.S., lower neutrophil and
leukocyte counts have been found to be more common among
blacks relative to whites [15]. To date, no studies have assessed
laboratory reference intervals in a controlled, systematic manner
across multiple African sites among asymptomatic adults who
would otherwise be eligible as healthy clinical trial volunteers.
Locally appropriate reference intervals are essential for planning
and executing trials in a safe, efficient and ethical manner.
This paper presents the results from a cross sectional study in seven
African research facilities to: 1) establish values for locally relevant
serum chemistry and hematology analytes among healthy African
adults in anticipation of future clinical trials of HIV prevention
technologies and other interventions, 2) compare these findings to
established intervals from the U.S., and 3) determine how many
individuals would have been reported as having an adverse event
(AE) according to the DAIDS AE Grading Table [16].
Methods
Ethical Considerations
This study was approved by the National Ethics Committee of
Rwanda, the Uganda Virus Research Institute Science and Ethics
Table 2. Hematology results, U.S.-based comparison intervals and out of range (OOR) values
OOR{
Analytes N
Study Consensus
interval Units
U.S.-based
Comparison interval* N %
Hemoglobin
Male 1083 12.2–17.7 g/dL 13.5–17.5 140 12.9
Female 1022 9.5–15.8 g/dL 12.0–16.0 169 16.5
Hematocrit 1
Male 799 35.0–50.8 % 41–53 151 18.9
Female 846 29.4–45.4 % 36–46 187 22.1
RBC2 1929 3.8–6.2 6106 cells/mL NA
Male 1083 4.0–6.4 6106 cells/mL 4.5–5.9 231 21.3
Female 846 3.8–5.6 6106 cells/mL 4.0–5.2 141 16.7
MCV 2105 68–98 fl 80–100 403 19.1
Platelets 2105 126–438 6103 cells/mL 150–350 360 17.1
Total WBC 2105 3.1–9.1 6103 cells/mL 4.5–11.0 602 28.6
Neutrophil count 2103 1.0–5.3 6103 cells/mL 1.8–7.7 604 28.7
Neutrophil (%) 2103 25–66 % 40–70 721 34.3
Lymphocyte count 2105 1.2–3.7 6103 cells/mL 1.0–4.8 18 0.9
Lymphocyte (%) 2105 23–59 % 22–44 798 37.9
Monocytes count 2103 0.20–0.78 6103 cells/mL 0–0.8 41 2.0
Monocytes (%) 2103 4.5–13.1 % 4–11 181 8.6
Eosinophils count 2104 0.04–1.53 6103 cells/mL 0–0.45 437 20.8
Eosinophils (%) 3 1921 0.8–21.8 % 0–8 361 18.8
Basophils count 4 1750 0.01–0.15 6103 cells/mL 0–0.2 22 1.3
Basophils (%) 5 1429 0.4–2.5 % 0–3 26 1.8
CD4 count 2100 457–1628 cells/mL 518–1981 109 5.2
CD8 count 2100 230–1178 cells/mL 270–1335 146 7.0
*[22], except differential counts [23] and CD4/CD8 counts [Beckton Dickson package insert]
{The number and percent of African values outside the U.S.-based comparison interval
1Excludes men from Kangemi and KNH, and women from Kangemi
2Excludes women from Kangemi
3Excludes men from Masaka
4Excludes all Lusaka volunteers
5Excludes all Lusaka and Entebbe volunteers, and women from Kilifi
doi:10.1371/journal.pone.0004401.t002
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Committee, the Uganda National Council for Science and
Technology, the Kenya Medical Research Institute Ethics
Committee, Kenyatta National Hospital Ethics and Research
Committee at the University of Nairobi, the University of Zambia
Biomedical Research Ethics Committee and the Emory University
School of Public Health Ethics Committee. All EC/IRBs are
registered with the U.S. Office of Human Research Protection.
Written informed consent was obtained prior to conducting any
study procedures, literacy was not a requirement for participation.
Reference populations
Healthy male and female volunteers aged 18–60 years with a
documented HIV-negative test in the prior four weeks were
screened and enrolled across seven clinical research centers in four
countries (Kigali, Rwanda; Masaka and Entebbe, Uganda;
Kangemi and Kenyatta National Hospital [KNH] in Nairobi and
Kilifi, Kenya; and Lusaka, Zambia). The methods have previously
been described in detail [17]. Briefly, 200 to 400 volunteers were
recruited at each site with equal numbers of men and women
represented by design. Volunteers were largely recruited from new
or ongoing cross-sectional and prospective cohort studies conducted
in preparation for future HIV vaccine safety and efficacy trials.
Potential volunteers were screened out if a medical history revealed
that they were acutely ill, had significant recent illness, or were
pregnant. Menstruating women were invited to return in two weeks.
Breastfeeding women were not excluded. At enrollment, demo-
graphic information and medical history were collected, a physical
examination was performed, and blood and urine samples were
collected. HIV counselling and testing was provided if the volunteer
did not have a documented negative HIV test performed in the
previous four weeks. Enrolled volunteers were excluded from the
study analysis if they had significant findings on physical
examination or if laboratory tests revealed that they were pregnant,
HIV antibody positive, had evidence of hepatitis B or C infection or
suspected syphilis.
Laboratory
Blood was tested for Hepatitis B surface antigen (Abbot-Murex
HBsAG ELISA version 3 or Biomerieux Hepanostika HBsAg Uni-
Form II MicroELISA system), Hepatitis C antibody (Abbot-Murex
Anti-HCV version 4 or Innogenetic Innotest HCV Ab IV), HIV
antibodies [17] and RPR serostatus. Urine pregnancy tests for hCG
were performed on all women. Blood was tested for 25 analytes
including clinical chemistry, hematology (complete blood count,
with 5-part automated differential and platelet count), and CD4 and
CD8 T cell count. All laboratories used the Beckman Coulter AcT 5
diff CP Hematology Analyzer (Beckman Coulter, USA) and the
Vitalab Selectra E Clinical Chemistry Analyzer (Vital Scientific,
The Netherlands). Four clinical centers (Kangemi, KNH, Entebbe,
and Masaka) did not to perform alkaline phosphatase (ALP) testing
Figure 1. Hemoglobin intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison
interval and cutoff for DAIDS grade one severity (vertical dashed line).
doi:10.1371/journal.pone.0004401.g001
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with the standardized reagents; these data are not shown. Five
laboratories used the FACSCount System (BD Biosciences, USA),
while the KAVI laboratory used the FACSCalibur (BD Biosciences,
USA). All machines were calibrated to record CD4 values $2,000
cells/mL as 2,000 cells/mL. To minimize CD4 diurnal variation,
samples were drawn before noon. Specimens with low CD4 counts
(,350 cells/mL) were tested for HIV RNA by polymerase chain
reaction (PCR, Roche Amplicor) to rule out antibody-negative,
acute HIV infection.
All laboratory staff received equipment training and were
required to pass an independent quality review before enrolling
volunteers. Analyte results were validated throughout the course of
the study through a central reference laboratory (Central
Laboratory Services [CLS], Johannesburg, South Africa) external
quality assurance (EQA) program provided by the South African
National Health Laboratory Services [18,19]. Results were
compared across technicians and across laboratories. The study
was conducted according to the principles of Good Clinical
Laboratory Practices [20].
Data collection and analysis
Data were directly recorded on Case Report Forms which were
then faxed to a central server using DataFax software (Clinical
DataFax Systems Inc., Hamilton, Canada). Data analyses were
conducted using Stata (v9.1 College Park, TX, USA) and SAS
(v9.1, Cary, NC, USA) software. The Clinical and Laboratory
Standards Institute (CLSI, www.clsi.org, formerly NCCLS) terms
and guidelines for defining reference intervals [21] were followed.
Briefly, we evaluated intervals by clinical centers and gender. If the
overall F-test from an ANOVA on mean values was statistically
significant (p,0.05), a step-wise procedure was performed to
evaluate which intervals were similar enough to combine into a
‘study consensus interval.’ For parameters that were long-tailed, all
ANOVA tests were performed after a log transformation and
geometric means were compared instead of the arithmetic means.
First, we compared the two most similar sites’ intervals based on
the p-values obtained from the overall ANOVA, which were
adjusted for multiple comparisons using the Tukey method. If not
statistically significantly different, then the data from the two sites
were combined. If significantly different, but the difference
between means was less than 25% of the width of the 95%
reference interval estimated from the combined sample, and the
ratio of standard deviations was less than 1.5, then the data from
the two sites were combined. The combined data were then
compared to each remaining site as described above in a new
ANOVA. This was repeated until all sites were combined into or
excluded from the study consensus interval. Finally, the study
consensus intervals for men and women were compared as above,
Figure 2. Neutrophil intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval
and cutoff for DAIDS grade one severity (vertical dashed line).
doi:10.1371/journal.pone.0004401.g002
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and the data combined if differences were not significant, as
described above. Study consensus intervals are shown as the 2.5th
and 97.5th percentiles between which lies 95% of our reference
sample group data.
Study consensus intervals were first compared to U.S.-derived
laboratory intervals from the Massachusetts General Hospital
(MGH) [22] for most analytes, from Bakerman’s ABCs of Interpretive
Laboratory Data [23] for white blood cell differentials (which are not
presented in the MGH data), and from the Becton Dickson
FACSCount package insert for CD4 and CD8 T cell counts.
Collectively, these U.S.-derived laboratory intervals will be
referred to as the ‘‘U.S.-based comparison intervals.’’ Because
these published comparison intervals do not provide details on
laboratory methodology, inclusion/exclusion criteria, sample sizes
or standard errors, statistical confirmation in comparing labora-
tory intervals was not possible. We present the number and
percent of volunteers in our study with out-of-range (OOR) values
when compared to the U.S.-based comparison intervals.
We then applied the AE grading criteria provided by Division of
AIDS, National Institute of Allergy and Infectious Diseases, of the
U.S. National Institutes of Health (DAIDS) [16] to determine how
many study volunteers would have been classified as having an AE.
These criteria consider 12 of the analytes presented in this report.
The DAIDS AE grading cutoffs for hematology are absolute
numbers, while the chemistry cutoffs are relative to the ‘‘normal’’
limits of a particular laboratory, site, or population. For the latter,
we applied the DAIDS AE criteria to the U.S.-based comparison
intervals described above in order to create the DAIDS-based AE
grading cutoffs for chemistries. We present the number and percent
of volunteers in our study who would have been classified as an AE
when using the U.S.-derived DAIDS AE grading criteria.
Results
Study population
From December 2004 to October 2006, a total of 2,990
potential volunteers were screened, of whom 2,387 (80%) were
enrolled and 2,105 (70%) were included in the final analysis. A
detailed report of the study population recruitment, enrollment
and exclusions has been published [17]. Volunteers who were
screened out by history and physical examination after informed
consent but prior to enrollment tended to be older than those
enrolled (median age: 30 vs. 28 years, respectively, p= 0.001) and
were more likely to be female (22.8% vs. 17.6% males, p,0.001).
Of those enrolled, 282 (12.0%) were excluded from analysis,
mainly due to a positive test for HBsAG (106, 40%), Hepatitis C
antibody (95, 36%), or a positive RPR (55, 21%). More males were
excluded from analysis, although the difference was not statistically
significant (12.5% vs. 9.4% females, p = 0.06). For a listing of all
values by clinical center and by gender, the complete study report
Figure 3. Eosinophil count intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison
interval.
doi:10.1371/journal.pone.0004401.g003
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may be found online (www.iavi.org/protocolD), or contact the
corresponding author.
The final analysis cohort of 2,105 comprised 1,022 (49%)
women and 1,083 (51%) men. The age range was 18–59 years
(median: 28) and varied by location (Table 1). The highest level of
education achieved also differed by location. The KNH cohort
primarily included medical and health professionals; the other sites
had more generalized urban and rural populations. Nearly 20% of
the Kigali cohort reported completing no formal education. The
majority of volunteers reported no alcohol use; only 94 (4.5%)
reported daily intake of alcoholic beverages. The greatest number
of smokers was reported in Kangemi (34%) and the lowest in
Entebbe (,2%). Reported recreational drug use was very low, and
94% of the cohort reported no use.
Hematology study consensus intervals
The hematology results are shown in Table 2. Due to significant
gender and site variability, the complete data set could not be used
to construct study consensus intervals for four of the 12 analytes
(hematocrit, RBC, eosinophils and basophils). Women had lower
hematocrit (median 39.7% vs. 45.1%, p,0.001) and lower
hemoglobin values than men (median 13.4 vs. 15.4 g/dL,
p,0.001) (Figure 1). Median hematocrit values for men and
women at Kangemi and men at KNH were significantly higher
than the study consensus interval and were therefore not included
in the consensus interval (for details, see complete study report). In
general, hematocrit values (and to a lesser degree, hemoglobin)
tended to be lower than the U.S.-based comparison interval. Over
20% (187/846) of women had hematocrit values that were OOR
(mostly lower) versus the U.S.-based comparison interval.
There was no significant gender or site variability for complete
WBC counts across our study populations. The study consensus
interval was lower than the U.S.-based comparison interval with
nearly 29% of values OOR. Neutrophil counts also tended to be
low (Figure 2), with a similar proportion of OOR values.
Eosinophil values tended to be high (Figure 3). The eosinophil
counts did not vary significantly by site or gender. Because
eosinophil percent were significantly higher among men in
Masaka, these values were not included in the study consensus
interval. Basophil counts and percent varied by site, and the study
consensus intervals do not include values from Lusaka. The study
consensus interval for basophil percent also excludes values from
Entebbe and women from Kilifi.
There were no significant site or gender differences in CD4
(Figure 4) or CD8 T cell intervals. Overall, the study consensus
interval for CD4 T cell counts was similar to the U.S.-based
comparison interval at 457 to 1640 cells/mL. Eight volunteers had
CD4 T cell counts $2000 cells/mL and were coded as 2000 cells/
Figure 4. CD4 count intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval
and cutoff for DAIDS grade one severity (vertical dashed line).
doi:10.1371/journal.pone.0004401.g004
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mL. Nine volunteers had CD4 T cell counts ,350 cells/mL,
(range: 160–333 cells/mL) none of whom had antibody or PCR
evidence of HIV infection. Few volunteers had values that were
OOR for CD4 (5.2%) or CD8 (7.0%) T cell counts (Table 2).
Chemistry study consensus intervals
The chemistry results are shown in Table 3. Due to significant
gender and site variability, we were unable to create study
consensus intervals using the complete data set for three of the 12
analytes (direct bilirubin, total immunoglobulin gamma [IgG], and
lactate dehydrogenase [LDH]). Our total and direct bilirubin
study consensus intervals were considerably wider than the U.S.-
based comparison intervals; 31% and 42% of study values were
OOR, respectively (Figures 5 and 6). The direct bilirubin interval
from women in Kilifi was significantly lower than the other
intervals from other sites, so values from women in Kilifi were
excluded from the study consensus interval.
Values for IgG, creatinine phosphokinase (CPK) and LDH
tended to be higher than their respective U.S.-based comparison
intervals. In particular, 83% of IgG values and .99% of LDH
values were OOR versus the U.S.-based comparison intervals.
The study consensus interval for IgG excluded values from men in
Masaka (Figure 7), and the study consensus interval for LDH
excluded all Lusaka volunteers and men from KNH (Figure 8).
The study consensus interval for amylase was 35–159 IU/L,
compared with 60–180 IU/L in the U.S., and there were no
significant differences by site or gender. Both aspartate amino-
transferase (AST, or SGOT) and alanine aminotransferase (ALT,
or SGPT) intervals were slightly higher than their respective U.S.-
based comparison intervals. Kangemi men had the highest levels
of both AST and ALT, and the highest reported rates of alcohol
intake were from this site (9% drink daily, 43% drink less than
daily).
‘‘Adverse Events’’ by U.S.-Derived Grading Criteria
When the DAIDS AE criteria were applied to the 12 analytes
evaluated in our study for which applicable values exist, a total of
744/2105 (35.3%) volunteers would have been considered to have
had at least one laboratory-based AE: 319 (15.2%) with a
hematology AE and 511 (24.3%) with a chemistry AE (Table 4).
Had this clinically healthy study population been in an actual
clinical trial, 3 volunteers would have been classified as having a
grade 4 (‘‘life threatening’’) AE: one due to low hemoglobin and
two due to elevated total bilirubin results. The prevalence of
laboratory ‘‘AEs’’ varied by analyte (range: 0–15%). Among
women, 67 (6.6%) hemoglobin values would have been classified
as an AE: 33 (3.2%) grade 1, 17 (1.7%) grade 2, 16 (1.6%) grade 3,
and 1 (0.1%) grade 4. Study consensus intervals for neutrophil
results tended to be lower than the U.S.-based comparison
interval, and 201 (9.6%) volunteers would have been classified as a
grade 1 or higher AE. Of these, 38 (1.8%) would have been
classified as grade 2 and 7 (0.3%) considered grade 3. Study AST
values also tended to be higher than the U.S.-based comparison
intervals with the following results: 103 (4.9%) grade 1, 20 (1.0%)
grade 2, and three (0.1%) grade 3. Study ALT values also tended
to be high classifying 132 AEs: 120 (5.7%) grade 1, 10 (0.5%)
grade 2 and two (0.1%) grade 3. Total bilirubin was the analyte
with the greatest difference from U.S.-based values, with nearly
15% of volunteers who would have been classified as having an
AE: 191 (9.1%) grade 1, 93 (4.4%) grade 2, 28 (1.3%) grade 3, and
2 (0.1%) grade 4.
Discussion
As the attention of the global health community increasingly
turns to the development of preventive and therapeutic interven-
tions for HIV, tuberculosis and malaria, among others, Africa has
Table 3. Chemistry results, U.S.-based comparison intervals, and out of range (OOR) values
Analytes N
Study Consensus
interval Units
U.S.-based Comparison
interval* OOR{
N %
Creatinine 2103 47–109 mmol/L 0–133 3 0.1
AST (SGOT) 2103 14–60 IU/L 0–35 244 11.6
ALT (SGPT) 2103 8–61 IU/L 0–35 248 11.8
Bilirubin direct 1 1906 0.4–8.8 mmol/L 1.7–5.1 792 41.6
Bilirubin total 2102 2.9–37.0 mmol/L 5.1–17 651 31.0
Total IgG 2 1919 759–2776 mg/dL 614–1295 1594 83.1
LDH 3 1674 214–528 IU/L 100–190 1663 99.3
Amylase 2103 35–159 IU/L 60–180 686 32.6
ALP 4 1021 48–164 IU/L 30–120 142 13.9
CPK 2101 53–552 IU/L NA
Male 1080 60–709 IU/L 60–400 119 11.0
Female 1021 49–354 IU/L 40–150 290 28.4
Albumin 2103 35–52 g/L 35–55 41 2.0
Total protein 1772 58–88 g/L 55–80 290 16.4
*[22]
{The number and percent of African values outside the U.S.-based comparison interval
1Excludes women from Kilifi
2Excludes men from Masaka
3Excludes all Masaka volunteers and males from KNH
4No data available from KNH, Kangemi, Entebbe or Masaka
doi:10.1371/journal.pone.0004401.t003
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become an important venue for clinical trials [1,24]. A thorough
understanding of the health status of potential clinical trial
volunteers in Africa is essential for planning and executing such
trials in a safe, efficient and ethical manner. In this regard, it is
essential to use locally appropriate laboratory reference intervals to
assess volunteer health, monitor laboratory-based AEs, and assure
that healthy individuals who want to volunteer to participate in
clinical trials are not unnecessarily prevented from participating if
it is safe for them to do so.
Our aim was to assess ‘‘normal’’ reference intervals in healthy,
HIV-uninfected adults most representative of the population likely
to enroll in future HIV prevention clinical trials and to compare
them to U.S.-derived reference intervals. Discussion about how to
define ‘‘normal’’ in the context of physiologic variation is far from
new: it has been debated since the seminal studies of Claude
Bernard in the 19th century [25]. In defining ‘‘normal’’ for clinical
trial participation, it seems desirable to study persons whose robust
health minimizes any concerns that an investigational product or
clinical procedure will cause harm, or that disease will distort the
results of the trial. Hence, this study excluded participants whose
medical history or physical examination indicated they were
unwell. By both their own judgment and the clinical trial
physicians’ evaluation, the participants in this study were healthy.
Application of reference intervals derived from populations of
different ethnicity and environment might appear to be more
conservative, but the primary question of trials in Africa is, and
should be, will this investigational product be safe and efficacious in this
population? To most efficiently answer that question, we believe that
reference intervals derived from African populations should be
used in selecting participants and evaluating adverse events in
future African research.
We found that several analytes that are used as inclusion criteria
for clinical trials differed significantly from the U.S.-based
comparison intervals. Study volunteers whose values for certain
analytes, particularly neutrophil counts and total bilirubin, fall on
the outer edge of the study consensus interval would be classified as
having a DAIDS Grade 1 or 2 adverse event despite being clinically
healthy adults. If such volunteers do not participate in future
preventive clinical trials, the trial results would be difficult to
generalize to the healthy population as a whole. The U.S. Food and
Drug Administration (FDA) recently created a toxicity assessment
scale [26] similar to that provided by DAIDS [16] but specifically
for use with preventive vaccine clinical trials. While the grading
criteria are very similar, the FDA grades analytes that DAIDS does
not (e.g. WBC and eosinophil counts), and it grades some analytes
more conservatively than DAIDS (e.g. CPK, lymphocyte counts,
neutrophil counts). Evaluating our data against the newer FDA
guidelines would classify an even greater proportion of our healthy
Figure 5. Total bilirubin intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison
interval and cutoff for DAIDS grade one severity (vertical dashed line).
doi:10.1371/journal.pone.0004401.g005
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volunteers than we report here as being ineligible for studies due to
having an ‘‘adverse event’’. Of note, the FDA document does
highlight the importance of considering locally appropriate clinical
reference values when grading AEs [26].
Hemoglobin, hematocrit and RBC values tended to be lower in
our study than in the U.S.-based comparison intervals. Similar
findings have previously been observed in healthy, HIV-uninfect-
ed populations in Uganda [11]. Lower hemoglobin levels have also
been reported in Ethiopia [9]. Possible explanations include poor
nutritional status resulting in iron deficiency, genetic disorders (e.g.
thalassemia, sickle cell trait), or infection with helminths or other
parasites (e.g. malaria or schistosomiasis) for which we did not test.
Pregnancy and childbirth may affect a woman’s hematologic
profile. These effects are largely transient, and we excluded from
analysis the data from pregnant women. It is important to include
healthy women in trials, given difficulties in recruiting and
retaining women in clinical trials [27]. When screening volunteers
for clinical trial participation, investigators must be aware that
repeated phlebotomy from clinical trial participation may
transiently decrease hemoglobin by as much as 1.0gm/dL [28].
Conversely, altitude can increase these hematologic parameters.
Participants at the two study centers in Nairobi had higher
hematocrit and RBC; these centers are at an elevation of 1680
meters and are the only centers that are not in a malaria-endemic
area. The KNH study population was primarily drawn from
medical students and clinicians, whose higher level of education
and socioeconomic status, and presumed better health status,
could also contribute to the hematological indices that differed
significantly from other African research centers warranting
exclusion from the consensus intervals per CLSI guidelines,
Depending on the location of the clinical research center, there
may also be seasonal variation in hematologic values due to
malaria. However a preliminary report on data collected from a
substudy across rainy and dry seasons in Kigali suggests that any
seasonal changes in analyte values are modest and of limited
clinical significance [29].
Lower neutrophil counts compared to western reference
intervals have been reported in African populations [5,10,11,30]
and among blacks in the U.S. [15]. Our study consensus interval
for neutrophil counts was lower than the U.S.-based comparison
interval, and nearly 10% of our study population would have been
classified as having a neutrophil count related AE. The lower
neutrophil count may reflect genetic and/or environmental
differences. We also found that basophils and eosinophils in both
Figure 6. Direct bilirubin intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison
interval.
doi:10.1371/journal.pone.0004401.g006
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genders were elevated relative to the U.S.-based comparison
intervals, likely due to a high prevalence of parasitic infections in
the study population and exposure to a broader range of
environmental antigens [31,32]. We did not perform malaria
blood smears on asymptomatic study volunteers. Malaria and
other parasitic infestations can induce eosinophilia. Malaria is
endemic at all participating study sites except Nairobi. Kangemi
and KNH volunteers had among the lowest eosinophil counts at
all the sites (Figure 3), although the difference was not sufficient to
exclude them from the consensus intervals. Preliminary results
from a sub-study examining stool for ova and parasites in Lusaka,
Entebbe and Kigali demonstrate the presence of ova or parasites
in as many as one third of stool samples (data not shown).
Studies in Uganda [13] and Tanzania [14] suggest that modest
differences across genders and between Western and African values
may exist for CD4 counts. One well-controlled study found lower
CD4 counts among 142 healthy HIV-uninfected Ethiopians
compared to 1,356 Dutch control volunteers [9]. Our study did not
demonstrate significant site or gender differences in CD4 T cell
counts, and our study consensus interval was similar to the U.S.-based
comparison interval. The different conclusions may be due to the fact
that the Ethiopian-Dutch study did not employ CLSI guidelines to
compare CD4 counts across study populations. With sufficient
sample sizes, standard statistical comparisons (e.g., student’s t test,
Wilcoxon rank sum) may detect a statistically significant difference
where the clinical significance is questionable [21].
We found a greater proportion of OOR values in clinical
chemistry results than in hematology results. The highest prevalence
of OOR values was found in LDH, IgG, and direct bilirubin. Neither
LDH nor IgG are included in the DAIDS AE tables or the FDA
guidelines for toxicity grading [16,26]. LDH is a non-specific
laboratory marker that can be elevated in several common disorders
or due to hemolysis during specimen collection and processing.
Although we did not collect data on specimen quality for analysis, the
study laboratories operated under quality assurance programs to
minimize issues with sample collection. The most common possible
causes of asymptomatic LDH elevation relevant to our study
population include anemia, skeletal muscle trauma due to physical
exertion, and asymptomatic liver disease. Although we did not
fractionate the LDH, we did not see clinically significant correlations
between elevated LDH and elevated hepatic transaminases or
indicators of anemia such as lower hemoglobin and hematocrit (data
not shown). Although 99% of the LDH values observed in this study
were outside the U.S.-based comparison interval, the lower limits of
our study consensus intervals did overlap with the reference intervals
from the Washington Manual (100–250 IU/L) [33] and Bakerman’s
Figure 7. IgG intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval.
doi:10.1371/journal.pone.0004401.g007
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ABCs (118–273 IU/L for men and 122–220 IU/L for women) [23].
Such a systematic difference in values for LDH may suggest a
difference in laboratory methods. However this cannot be confirmed
because the reference texts for the U.S.-based comparison intervals
do not provide laboratory methodologies. The elevated IgG may be
due to the larger burden of immunological challenges associated with
infectious agents prevalent in a tropical environment and/or a
developing country [31,32].
The highest proportion of events that would be classified as AEs
in a clinical trial was observed in total bilirubin. Possible
explanations for an elevated total bilirubin in our study population
include hemolysis secondary to malaria or sickle cell trait,
malnutrition, physical exertion, and cirrhosis, although conditions
such as Gilbert’s syndrome, which has been reported in South
Africa [34], cannot be ruled out. High levels of reported alcohol
intake were not common in this population, and volunteers with
jaundice or laboratory evidence of chronic hepatitis B or C were
excluded from enrollment and analysis. We also observed a high
frequency of elevated direct bilirubin that varied by location and
gender. The causes of elevated direct bilirubin are frequently
related to hepatocellular disease, biliary tract obstruction, and
inherited syndromes which usually have clinical manifestations.
However, the population was carefully screened by history and
physical examination, and we did not see a correlation between
either AST or ALT and total or direct bilirubin in asymptomatic
volunteers (data not shown). Previous IAVI-sponsored Phase I
HIV vaccine trials in Kenya and Uganda found high bilirubin
levels in several healthy volunteers with no concurrent elevation in
transaminases [35] Therefore, we feel hepatic disease is an unlikely
explanation for the many OOR chemistry liver function tests in
our study populations. The role of environmental factors remains
unclear.
The approach to defining consensus reference intervals is
complex. We have chosen to apply the CSLI method for
combining values from different groups. As recommended by
the CLSI guidelines, we did not censor outliers from our data set
from volunteers who were otherwise eligible for inclusion. The
results presented include three clinically healthy individuals whose
laboratory values for hemoglobin and total bilirubin would have
been considered as Grade 4 AE (‘‘potentially life threatening’’)
according to DAIDS grading criteria. Excluding outliers is
discussed by Horn et al. with regards to hospital-generated ranges
[36,37], where the likelihood of including individuals with disease
is high. Our study populations were carefully screened to exclude
Figure 8. LDH intervals and medians by site and gender (men: blue, women: white) including U.S.-based comparison interval.
doi:10.1371/journal.pone.0004401.g008
African Reference Intervals
PLoS ONE | www.plosone.org 12 February 2009 | Volume 4 | Issue 2 | e4401
unwell persons, and clinical reference intervals based on ranked
observations and with our sample size are not significantly affected
by the inclusion of potential outliers [21]. Additionally, methods to
identify and censor outliers remain unsatisfactory [38].
Given the large sample size at each research center, we found
numerous statistically significant (p,0.05) differences across sites
and gender that did not merit excluding those populations from
the consensus intervals. Sub-group comparisons based on the
differences in means rather than the interval endpoints themselves
may affect the final consensus intervals. We found, for example,
that while we were able to create a consensus interval for
neutrophils from all sites, the upper limits of the Kenyan intervals
were consistently higher than what we observed at other sites
(Figure 2). While the CLSI guidelines do consider interval
variability to some degree, the significance of creating a consensus
reference interval without a direct comparison of the upper and
lower limits is unclear. A possible remedy might include regression
analysis performed on percentiles, rather than only on the mean
value (e.g., the SAS QUANTREG procedure).
Furthermore, the CLSI guidelines do not provide clear
guidelines on how to proceed when comparing multiple sub-
groups. We chose to do a stepwise analysis as described in the
methods. This was first performed separately by site, then for
males and females. Another approach might be to combine the
data from sites in no particular order; or to first combine data from
all sites, then to remove one site at a time (i.e., backwards
elimination). With multiple sites under study, these approaches
might result in different or multiple distinct groups. These
observations will be the basis of future work and suggest that the
CLSI guidelines may need to be revisited if it is desired to establish
region-wide ranges.
Our study populations were selected on the basis of their
willingness to receive VCT and participate in HIV-related
research. This potential selection bias limits the ability to
generalize these results to the entire adult population of the
region. Although we were able to create study consensus intervals
for the majority of the analytes measured, some analyte intervals
were not compatible across study sites or populations. This further
underscores the importance of using locally appropriate laboratory
reference intervals for public health and research studies. For those
research centers without locally-derived reference intervals, a
regionally-derived consensus interval and sound clinical judgment
may be the next best alternative until more data become available.
In all situations, the volunteer participant’s health and safety is of
utmost priority.
Conclusions
Clinical trials of interventions intended for use in Africa should
enroll healthy persons who are representative of the population
that will receive the intervention. Exclusion of eligible volunteers
based on reference ranges derived from a different population
creates unnecessary delays in enrolment. Applying non-local
reference intervals for hematology and biochemistry screening
and grading of AEs would have excluded over one-third of these
healthy Africans from trial participation. Furthermore, the use of
non-local laboratory reference intervals in clinical research may
ultimately compromise the scientific validity of clinical trial
conclusions by selecting participants that are not representative
of the source population. This work successfully created a set of
consensus intervals for the majority of analytes studied, however
local conditions such as elevation, endemic diseases, and
nutritional factors must be taken into account. These study
findings on laboratory intervals from healthy African volunteers
will be useful in the design, conduct, and evaluation of future
clinical trials and highlight the need for local data.
Table 4. Analyte results and frequency of ‘‘adverse events’’ graded against western-derived DAIDS AE cutoffs*
Grade 1 Grade 2 Grade 3 Grade 4
Analytes N
Study
Consensus
interval Units Cutoff N % Cutoff N % Cutoff N % Cutoff N %
Hemoglobin
Male 1083 12.2–17.7 g/dL #10.9 2 0.2 #9.9 1 0.1 #8.9 3 0.3 #7.0 0 0
Female 1022 9.5–15.8 g/dL #10.9 33 3.2 #9.9 17 1.7 #8.9 16 1.6 #7.0 1 0.1
Platelets 2105 126–438 610^3 cells/mL #124.9 28 1.3 #99.9 18 0.9 #49.9 5 0.2 #25 0 0
WBC 2105 3.1–9.1 610^3 cells/mL #2.5 6 0.3 #1.9 0 0 #1.49 0 0 #1 0 0
Neutrophil count 2103 1.0–5.3 610^3 cells/mL #1.3 156 7.4 #0.99 38 1.8 #0.749 7 0.3 #0.5 0 0
Lymphocyte count 2105 1.2–3.7 610^3 cells/mL #0.65 0 0 #0.59 0 0 #0.49 0 0 #0.35 0 0
CD4 2100 457–1628 cells/mL #400 11 0.5 #299 3 0.1 #199 1 0.1 #100 0 0
Creatinine 2103 47–109 mmol/L $146.3 0 0 $186.2 0 0 $252.7 0 0 $465.5 0 0
AST (SGOT) 2103 14–60 IU/L $43.8 103 4.9 $91.0 20 1.0 $178.5 3 0.1 $350.0 0 0
ALT (SGPT) 2103 8–61 IU/L $43.8 120 5.7 $91.0 10 0.5 $178.5 2 0.1 $350.0 0 0
Bilirubin total 2102 3.9–37.0 mmol/L $18.7 191 9.1 $27.2 93 4.4 $44.2 28 1.3 $85.0 2 0.1
Albumin 2103 35–52 g/L #35.0 52 2.5 #29.0 1 0.1 #20 0 0 NA
CPK
Male 1080 60–709 IU/L $1200 7 0.7 $2400 1 0.1 $4000 2 0.2 $8000 0 0
Female 1021 49–354 IU/L $450 9 0.9 $900 2 0.2 $1500 0 0 $3000 0 0
*Chemistry cutoffs [16] derived from [22]. Hemoglobin, platelets, WBC, neutrophil, lymphocyte and CD4 counts provided in [16]
doi:10.1371/journal.pone.0004401.t004
African Reference Intervals
PLoS ONE | www.plosone.org 13 February 2009 | Volume 4 | Issue 2 | e4401
Acknowledgments
We thank the study participants who agreed to join this study, frequently
after learning about the importance of HIV vaccine clinical trials through
community outreach activities of the clinical centers that hosted this work.
We thank Helen Thomson, Marietta Krebs, Andrea van Lieven, and
Barbara Ericksen for their important contributions to this work. We
acknowledge the support and enthusiasm of the late Professor Job Bwayo
for vaccine related research activities.
Author Contributions
Conceived and designed the experiments: NK MAP PK JG GS PF AK.
Performed the experiments: EK KK PK AN OAWJ GM ER JM EJS MM
SA AB UB KA GO BF JB ES OM PH AK. Analyzed the data: EK MAP
KK PNA SY LD JS. Contributed reagents/materials/analysis tools: BF
LSJ JG GS OM PH JS WS. Wrote the paper: EK MAP KK OA EJS SA
PNA LSJ LD WS PF AK.
References
1. Excler JL (2006) AIDS vaccine efficacy trials: expand capacity and prioritize.
‘Throughout Africa, Asia and Latin America state-of-the-art clinics and
laboratories...exist where, 4 years ago, there were none’. Expert Rev Vaccines
5: 167–170.
2. Jaoko W, Manyonyi G, Bhatt K, Anzala O, Ogutu H, et al. Screening failure in
a phase I HIV vaccine trial in Nairobi; 2006; Amsterdam, The Netherlands.
3. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, et al. (2008)
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine
candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara
(MVA) in humans in East Africa. Vaccine 26: 2788–2795.
4. Azikiwe AN (1984) Platelet count values in healthy Nigeria medical students in
Jos. East Afr Med J 61: 482–485.
5. Badenhorst CJ, Fourie J, Steyn K, Jooste PL, Lombard CJ, et al. (1995) The
haematological profile of urban black Africans aged 15-64 years in the Cape
Peninsula. East Afr Med J 72: 19–24.
6. Bain BJ (1996) Ethnic and sex differences in the total and differential white cell
count and platelet count. J Clin Pathol 49: 664–666.
7. Gill GV, England A, Marshal C (1979) Low platelet counts in Zambians.
Trans R Soc Trop Med Hyg 73: 111–112.
8. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, et al.
(2003) Immunohematological reference ranges for adults from the Central
African Republic. Clin Diagn Lab Immunol 10: 443–445.
9. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, et al. (1999)
Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab
Immunol 6: 410–414.
10. Ezeilo GC (1972) Non-genetic neutropenia in Africans. Lancet 2: 1003–1004.
11. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, et al. (2004)
Population-based hematologic and immunologic reference values for a healthy
Ugandan population. Clin Diagn Lab Immunol 11: 29–34.
12. Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, et al. (2001) Distribution of
lymphocyte subsets in healthy human immunodeficiency virus-negative adult
Ethiopians from two geographic locales. Clin Diagn Lab Immunol 8:
1171–1176.
13. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, et al. (1995)
Hematological reference ranges among healthy Ugandans. Clin Diagn Lab
Immunol 2: 233–235.
14. Urassa WK, Mbena EM, Swai AB, Gaines H, Mhalu FS, et al. (2003)
Lymphocyte subset enumeration in HIV seronegative and HIV-1 seropositive
adults in Dar es Salaam, Tanzania: determination of reference values in males
and females and comparison of two flow cytometric methods. J Immunol
Methods 277: 65–74.
15. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007)
Prevalence of Neutropenia in the U.S. Population: Age, Sex, Smoking Status,
and Ethnic Differences. pp 486–492.
16. DAIDS (2004) Division of AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events. Bethesda, MD, USA: DAIDS.
17. Stevens W, Kamali A, Karita E, Anzala O, Sanders EJ, et al. (2008) Baseline
Morbidity in 2,990 Adult African Volunteers Recruited to Characterize
Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials. PLoS
ONE 3: e2043.
18. Bland JM, Altman DG (1986) Statistical method for assessing agreement
between two methods of clinical measurement. The Lancet i: 307–310.
19. Scott LE, Galpin JS, Glencross DK (2003) Multiple method comparison:
statistical model using percentage similarity. Cytometry B Clin Cytom 54:
46–53.
20. Stiles T, Grant V, Mawbey N (2003) Good clinical laboratory practice (GCLP):
A quality system for laboratories that undertake the analysis of samples from
clinical trials. Suffolk, United Kingdom: British Association of Research Quality
Assurance (BARQA).
21. National Committee on Clinical Laboratory Standards (NCCLS) (2000) How to
define and determine reference intervals in the clinical laboratory; Approved
guideline, second edition. Wayne, PA, USA: NCCLS C28-A2, vol 20(13).
22. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB (2004) Laboratory reference
values. N Engl J Med 351: 1548–1563.
23. Bakerman S, Bakerman P, Stausbauch P (2002) ABC’s of Interpretive
Laboratory Data. Scottsdale. AZ, USA: Interpretive Laboratory Data, Inc.
24. Fast P, Excler J-L, Warren M, Ketter N (2007) Clinical site development and
preparation for AIDS vaccine efficacy trials in developing countries. In: Koff W,
Kahn P, Gust I, eds. AIDS Vaccine Development. Norfolk, UK: Caister
Academic Press.
25. Canguilhem G (1989) The Normal and the Pathological. Fawcell CR, translator.
New York, NY: Zone Books.
26. FDA (2007) Guidance for Industry: toxicity grading scale for healthy adult and
adolescent volunteers enrolled in preventive vaccine clinical trials. Rockville,
MD: FDA.
27. IAVI (2004) Gender in AIDS vaccine trials - Addressing challenges in
developing countries. New York: International AIDS Vaccine Initiative.
28. Mehendale S, Sahasrabudhe S, Kakade M, Shrotri A, Thakar M, et al. Frequent
large blood draws and decrease in hemoglobin levels among AIDS vaccine trial
participants in India; 2006 29 August–1 September, 2006; Amsterdam, The
Netherlands. Antiviral Therapy, 193 p.
29. Karita E, Kayitenkore K, Muvunyi C, Shutes E, Kambili C, et al. Seasonal
variation in clinical laboratory parameters among HIV-uninfected adults in
Kigali, Rwanda; 2006 29 August - 1 September, 2006; Amsterdam, The
Netherlands. Antiviral Therapy, 226 p.
30. Wane J (1985) Etude des valeurs de reference de quelques parametres
biologiques de l’adulte jeune en milieu urbain Zairois. Kinshasa, DRC:
Cliniques Universitaires du Mont Amba.
31. Lugada ES, Mermin J, Asjo B, Kaharuza F, Downing R, et al. (2004)
Immunoglobulin levels amongst persons with and without human immunode-
ficiency virus type 1 infection in Uganda and Norway. Scand J Immunol 59:
203–208.
32. Saathoff E, Schneider P, Kleinfeldt V, Geis S, Haule D, et al. (2008) Laboratory
reference values for healthy adults from southern Tanzania. Trop Med Int
Health 13: 612–625.
33. Cooper DH, Krainik AJ, Lubner SJ, Reno HEL, eds (2007) The Washington
Manual of Medical Therapeutics. 32nd Edition ed. St Louis: Lippincot Williams
& Wilkins.
34. Gitlin N (1977) The clinical presentation of Gilbert’s disease in 26 patients. S Afr
Med J 52: 19–20.
35. Jaoko W, Nakwagala FN, Anzala O, Omosa GM, Birungi J, et al. (2008) Safety
and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates
vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in
humans in East Africa. Vaccine 26: 2788–2795.
36. Horn PS, Feng L, Li Y, Pesce AJ (2001) Effect of outliers and nonhealthy
individuals on reference interval estimation. Clin Chem 47: 2137–2145.
37. Horn PS, Pesce AJ (2003) Reference intervals: an update. Clin Chim Acta 334:
5–23.
38. Solberg HE, Lahti A (2005) Detection of outliers in reference distributions:
performance of Horn’s algorithm. Clinical Chemistry 51: 2326–2332.
African Reference Intervals
PLoS ONE | www.plosone.org 14 February 2009 | Volume 4 | Issue 2 | e4401
